on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Highlights Safety of NFL-101 in New Study
NFL Biosciences has announced positive results from a new toxicity study evaluating its drug NFL-101, aimed at treating tobacco addiction. The study confirmed an exceptional safety profile for the drug, even at doses over 600 times the clinical level. These findings reinforce NFL-101's benefit-risk ratio, crucial for regulatory discussions and potential industry partnerships.
The study involved administering increasing doses to rats, showing no systemic or local toxicity. NFL-101 demonstrated a significantly better safety profile compared to existing treatments such as nicotine, cytisine, and varenicline. Genotoxicity and mutagenicity tests also showed no genetic risks, enhancing NFL-101's appeal as a safer alternative.
CEO Bruno Lafont emphasized the positive impact on regulatory discussions, highlighting the potential for NFL-101 to improve tobacco addiction management. The company targets a Phase 3 development plan to bring NFL-101 to the market in the near future.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news